Research programme: rho-associated protein kinase-2 inhibitors - HitGen

Drug Profile

Research programme: rho-associated protein kinase-2 inhibitors - HitGen

Alternative Names: ROCK2 inhibitors - HitGen

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator HitGen
  • Class Antiglaucomas; Antihypertensives; Antineoplastics; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Glaucoma; Liver cancer; Non-small cell lung cancer; Pulmonary arterial hypertension

Most Recent Events

  • 02 Mar 2017 Rho-associated protein kinase-2 inhibitors - HitGen is available for licensing as of 02 Mar 2017. http://www.hitgen.com/?page_id=7107 (HitGen pipeline, March 2017)
  • 02 Mar 2017 early research in Glaucoma in China (PO) before March 2017 (HitGen pipeline, March 2017)
  • 02 Mar 2017 Early research in Liver cancer in China (PO) before March 2017 (HitGen pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top